Truely regenerative cartilage product candidate

Program BN-02

  • Single treatment cycle of intra-articular application leads to long-term benefits

  • First in class product candidate due to unique mode of action

    • Inhibition of progressive cartilage destruction

    • Restoration of damaged cartilage via chondrocyte activation

  • Effects on pain

  • Pre-clinical development of BN-02 is nearly completed

    • Seven pharmacodynamics studies in small and large animals

    • Long term observation in large animals

    • GLP tox studies

  • Sound Prove of Concept data (POC) from relevant state of the art animal models; strong in vivo data package

  • Translatable biomarker for clinical trials: reduced clinical development effort; cost efficient route to clinical Prove of Concept